PitchSend

Half-Year 2022 Financial and Clinical Trials Update

Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication 1L ER+/HER2-positive breast cancer (BC) Phase/study # of patients Induction Phesgo plus taxane followed by maintenance with either: ARM A: Giredestrant plus Phesgo Design " ARM B: Phesgo Primary endpoint Status CT Identifier ■ Progression-free survival FPI Q2 2022 Phase III heredERA N=812 NCT05296798 ER-Estrogen receptor; HER2-Human Epidermal growth factor Receptor; Phesgo=FDC of Perjeta and Herceptin for SC administration; 137 Roche Oncology

View entire presentation